AI Summary Kalydeco (ivacaftor) is a CFTR potentiator for cystic fibrosis with responsive CFTR mutations and is not specifically indicated to treat liver disease.
Medically reviewed.
Kalydeco (ivacaftor) is a prescription CFTR potentiator. It treats cystic fibrosis (CF) in people who have specific responsive CFTR gene mutations. It helps CFTR proteins that are already at the cell surface work better, which supports lung function and overall CF care. People with CF can develop liver disease, but Kalydeco is not specifically indicated to treat it. Treatment decisions should always be individualized and guided by a healthcare professional.
This page covers Kalydeco in CF care: how it works, who may be prescribed it, how it is used, benefits, side effects, and monitoring, including liver tests. You can also connect with a liver specialist near you for personalized guidance on your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ABOUT KALYDECO TREATMENT
Kalydeco is a prescription medicine that contains ivacaftor. It is a CFTR potentiator. Doctors use it to treat cystic fibrosis (CF) in people who have specific responsive CFTR gene mutations.
Unlike combination CFTR modulators, such as Trikafta and Orkambi, ivacaftor works on CFTR proteins that are already at the cell surface. It improves how they move chloride across cells, which helps address the underlying cause of CF.
People with CF may develop liver disease, called cystic fibrosis–associated liver disease (CFLD). Treatment may also support overall liver health. Kalydeco is not specifically indicated to treat liver disease.
WHO KALYDECO MAY BE SUITABLE FOR
Whether you may be prescribed Kalydeco depends on your diagnosis, your genetic test results, and your individual health needs. Your healthcare provider may prescribe it if you have CF with a responsive CFTR mutation and genetic testing confirms you are eligible for ivacaftor therapy. It may also be considered when you need treatment to improve CFTR channel function or you have lung (pulmonary) symptoms of CF.
Dosing can vary with age, body weight, and the form of the medicine. It may also need adjusting if you have liver impairment or take certain other medications.
Because every patient's health profile is different, this decision belongs to a qualified healthcare professional after a full assessment.
ELIGIBILITY OVERVIEW
Kalydeco may be considered for people with the following conditions or treatment goals:
Before recommending Kalydeco, healthcare providers evaluate several factors, including:
HOW KALYDECO CAN HELP
In CF, the CFTR protein does not move chloride and water across cells as it should. Kalydeco enhances the opening of the CFTR chloride channel on proteins that are already at the cell surface. This improves the movement of chloride and water across epithelial cells.
This helps thin mucus and improve airway clearance. It can improve lung function and nutritional status. In eligible mutations, it treats the underlying protein defect.
Kalydeco is not used on its own. Your care team pairs it with regular monitoring, such as Liver Function Tests (LFTs), and standard CF care.
HEALTH BENEFITS
In CF, the CFTR protein does not move chloride and water across cells as it should. Kalydeco enhances the opening of the CFTR chloride channel on proteins that are already at the cell surface. This improves the movement of chloride and water across epithelial cells.
Better chloride and water movement helps thin mucus. Thinner mucus is easier to move, which improves airway clearance. Your care team will still advise you to keep up regular airway clearance therapy alongside Kalydeco.
Kalydeco can improve lung function and nutritional status in people with CF. It helps improve breathing and respiratory function, and it may reduce pulmonary exacerbations, which are flare-ups of lung symptoms. Results vary from person to person.
Unlike combination CFTR modulators, Kalydeco works on CFTR proteins that are already at the cell surface. In eligible CFTR mutations, it treats the underlying protein defect. It is not specifically indicated to treat cystic fibrosis–associated liver disease, though treatment may also support overall liver health.
Kalydeco helps CFTR proteins work better in people with responsive CFTR mutations. It should only be started and monitored under the guidance of a qualified healthcare professional.
TREATMENT PROCESS
Kalydeco comes as oral tablets. Oral granules are available for younger children. Take it exactly as your healthcare provider prescribes.
The Liver Therapies Patient Guide lists typical adult and eligible pediatric dosing as one 150 mg ivacaftor tablet by mouth every 12 hours (twice daily). Pediatric dosing may vary with age, body weight, and form. Your provider may adjust the dose if you have liver impairment or take certain other medications.
Take Kalydeco with fat-containing food about every 12 hours. Use it exactly as your healthcare provider directs, and do not change your dose without medical guidance.
Kalydeco is a long-term, ongoing therapy. It is typically continued indefinitely in eligible patients as long as it helps and is well tolerated. Do not stop taking it without first talking to your healthcare provider.
Store Kalydeco at room temperature, away from moisture and heat.
Your healthcare provider will regularly check liver function tests and how well treatment is working. Children also need eye (ophthalmologic) exams. Report any side effects or unusual symptoms to your healthcare provider.
BENEFITS AND SAFETY
Kalydeco (ivacaftor) is a precision therapy. It targets specific CFTR mutations linked to cystic fibrosis and improves the activity of the CFTR protein at the cell surface. It can help improve breathing and lung function. It may also reduce pulmonary exacerbations (flare-ups of lung symptoms) and improve nutritional status.
The extent of these benefits varies from person to person. Kalydeco is not specifically indicated to treat cystic fibrosis–associated liver disease. It works best as part of standard CF care, with regular monitoring like Liver Function Tests (LFTs).
As with any medication, Kalydeco may cause side effects. One of them is elevated liver enzymes, so your healthcare provider will monitor your liver function during treatment and assess whether Kalydeco remains a suitable option for you.
BENEFITS
Kalydeco is a CFTR potentiator. It improves the activity of the CFTR protein at the cell surface and the movement of chloride across cells. In eligible mutations, this addresses the underlying protein defect behind CF.
Kalydeco helps improve breathing and respiratory function in people with CF. It does this by helping thin mucus and improve airway clearance.
Kalydeco may reduce pulmonary exacerbations, which are flare-ups of lung symptoms, and improve nutritional status. Together, these effects can improve quality of life. The extent of benefit varies from person to person.
In people with cystic fibrosis–associated liver disease, treatment may also support overall liver health. Kalydeco is not specifically indicated to treat liver disease, so your provider will keep checking your liver function tests during treatment.
Your healthcare provider will discuss the potential benefits and risks before treatment. Regular liver function tests help catch elevated liver enzymes early. Report any side effects or unusual symptoms to your provider.
SUPPORTING YOUR RESULTS
Lifestyle habits are an important part of CF care alongside Kalydeco. The Liver Therapies Patient Guide advises regular airway clearance, good hydration, and taking doses with fat-containing meals.
These habits can support how your body responds to treatment over time.
Areas that may support treatment:
common questions
You may be eligible for Kalydeco if you have cystic fibrosis (CF) with a responsive CFTR mutation. Genetic testing confirms whether you qualify for ivacaftor therapy, so that result is the key step. Your provider also considers whether you need treatment to improve CFTR channel function or have lung symptoms of CF, along with your age, weight, liver function, and other medications. Ask your provider whether Kalydeco fits your situation.
Kalydeco helps CFTR proteins work better, which can improve lung function and nutritional status in people with CF. By improving chloride and water movement, it helps thin mucus and improve airway clearance. It may also reduce pulmonary exacerbations, which are flare-ups of lung symptoms. Results vary from person to person, so talk with your healthcare provider about what to expect and how your progress will be tracked.
No, Kalydeco is not specifically indicated to treat liver disease. It treats cystic fibrosis in people with responsive CFTR mutations. In people with cystic fibrosis–associated liver disease, treatment may also support overall liver health. Kalydeco does not replace liver care, so ask your care team how liver disease fits into your CF plan and whether you need a liver specialist.
Take Kalydeco with fat-containing food about every 12 hours. The Liver Therapies Patient Guide lists typical adult and eligible pediatric dosing as one 150 mg tablet twice daily. Oral granules are available for younger children. Pediatric dosing may vary with age, weight, and form, and your provider may adjust the dose for liver impairment or certain medications. Follow your provider's directions and do not change your dose on your own.
Common side effects of Kalydeco include headache, upper respiratory tract infection, abdominal pain, diarrhea, and elevated liver enzymes. Your healthcare provider will discuss the potential benefits and risks with you before treatment. Regular liver function tests help catch elevated liver enzymes early. Report any side effects or unusual symptoms to your healthcare provider, and do not stop taking Kalydeco without talking to them first.
Your healthcare provider will check liver function tests regularly while you take Kalydeco. Elevated liver enzymes are a possible side effect, so these blood tests help catch changes early. Providers also review how well treatment is working. Children also need eye (ophthalmologic) exams. Ask your care team how often you will be tested and what results would change your plan.
Kalydeco is a long-term therapy that is typically continued indefinitely. Doctors usually continue it in eligible patients as long as it helps and is well tolerated. Do not stop taking it without first talking to your healthcare provider. Your care team will review your treatment response at regular visits, so ask how often to expect those reviews and what would lead to a change.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
